Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
|Articles|June 11, 2007
- Summer 2007
- Volume 6
- Issue 4
Living Fully With and Beyond Cancer
Author(s)Elizabeth Whittington
The Anderson Network's Living Fully with and Beyond Cancer conference in Houston.
Advertisement
The Anderson Network at M.D. Anderson Cancer Center in Houston hosts Living Fully with and Beyond Cancer, its annual conference for cancer patients and caregivers. The weekend program, to be held September 6-8, will feature sessions on exercise, treatment side effects, caregiving issues, and many other topics. For details, visit
Articles in this issue
about 17 years ago
How to Find Helpabout 17 years ago
Job Transitions, Insurance Changeabout 17 years ago
Medicare Coverage for Colon Cancer Screeningsabout 17 years ago
Noting Group Differencesover 17 years ago
The Journey of Cancer Survivorshipover 17 years ago
Beauty Shoppingover 17 years ago
Pregnancy After Cancerover 17 years ago
Fast Facts: Richard Roundtreeover 19 years ago
Portal Authorityover 19 years ago
Precious TumorAdvertisement
Related to this article
A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.
Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.
The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.
Cancer research is increasingly looking beyond the tumor to understand the whole body, immune system and patient experience.
AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.
In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.
An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.
Advertisement
Advertisement
Trending on CURE
1
The Growing Role of AI in Cancer Care
2
Finding the Words: How to Talk to Someone With Cancer
3
3 More Lung Cancer Breakthroughs From WCLC 2026
4
Why Some Stage 3 Lung Cancers Don't Respond to Treatment, and What Researchers Are Trying Next
5